Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 5/20 | 0.46 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.46 |
| ▸ | ATG7 | O95352 | 4/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.46 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.46 |
| ▸ | UBA7 | P41226 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867137 | 1.00 | NAE1 (0.46) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL866315 | 0.87 | ATG7 (0.43) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL867742 | 0.87 | ATG7 (0.43) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL865428 | 0.86 | NAE1 (0.65) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL865998 | 0.86 | NAE1 (0.65) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL867224 | 0.86 | NAE1 (0.65) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL866573 | 0.83 | ATG7 (0.48) | ATG7 | |
| SCHEMBL866882 | 0.83 | ATG7 (0.48) | ATG7 | |
| SCHEMBL864989 | 0.83 | ATG7 (0.40) | NAE1UBA3ATG7SAE1UBA6 | |
| SCHEMBL867260 | 0.83 | ATG7 (0.40) | NAE1UBA3ATG7SAE1UBA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | claimed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | NAE1 2/4885UBA3 3/4885ATG7 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.